




Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the JP Morgan Healthcare Conference
Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the JP Morgan... -- SAN DIEGO, Calif., Dec. 24, 2012 /PRNewswire/ --
SAN DIEGO, Calif., Dec. 24, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]) today announced that management will present a company overview at the JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 8, 2013 at 10:30 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at [ www.orexigen.com ]. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at [ www.orexigen.com ].
Orexigen Contact: | Media Contact: |
McDavid Stilwell | Denise Powell |
VP, Corporate Communications and Business Development | WCG |
(858) 875-8629 | (510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
RELATED LINKS
[ http://www.orexigen.com ]